{"id":"cabotegravir-cab-la","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions (pain, induration, erythema)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Pyrexia"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the host cell genome, thereby halting HIV replication. The long-acting formulation (CAB LA) is administered as an intramuscular injection, providing sustained drug levels over weeks to months.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:39.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting intramuscular formulation)"},{"name":"HIV-1 prevention in at-risk individuals (PrEP indication under investigation)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT05996471","phase":"PHASE2","title":"A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-08-17","conditions":"HIV Infections","enrollment":185},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT06694805","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-12-02","conditions":"HIV Infections","enrollment":332},{"nctId":"NCT05986084","phase":"PHASE4","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Pre-Exposure Prophylaxis (PrEP), Breast Feeding","enrollment":500},{"nctId":"NCT06159894","phase":"NA","title":"Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of \"HIV Units\".","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2023-12-18","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT06411223","phase":"PHASE2","title":"Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-08-01","conditions":"Hiv","enrollment":50},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT07370649","phase":"","title":"Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","status":"NOT_YET_RECRUITING","sponsor":"Pomeranian Medical University Szczecin","startDate":"2026-02-01","conditions":"Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection, HIV-1 Subtype B Infection","enrollment":250},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05799339","phase":"","title":"Optimizing CAB-LA as PrEP for Women Who Inject Drugs","status":"COMPLETED","sponsor":"Alexis Roth","startDate":"2022-01-13","conditions":"HIV Infections, Opioid Use, Trauma, Psychological","enrollment":144},{"nctId":"NCT06134362","phase":"PHASE3","title":"Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-05-14","conditions":"HIV Infections","enrollment":3508},{"nctId":"NCT07275606","phase":"PHASE1, PHASE2","title":"A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1","status":"NOT_YET_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-03-17","conditions":"HIV Infections","enrollment":66},{"nctId":"NCT06451341","phase":"","title":"IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2024-07-01","conditions":"HIV","enrollment":55},{"nctId":"NCT06970223","phase":"PHASE1","title":"A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-04-22","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT06741397","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-12-20","conditions":"HIV Infections","enrollment":229},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT06336434","phase":"PHASE1, PHASE2","title":"CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-01","conditions":"HIV-1-infection, Pregnancy, Postpartum","enrollment":""},{"nctId":"NCT06868641","phase":"NA","title":"The TAIL-PrEP Study","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT06185452","phase":"PHASE4","title":"Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2023-09-26","conditions":"HIV-1 Infection","enrollment":103},{"nctId":"NCT06786520","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-01-17","conditions":"HIV Infections","enrollment":69},{"nctId":"NCT05601128","phase":"PHASE3","title":"A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA","status":"COMPLETED","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2023-01-01","conditions":"HIV-1-infection, HIV Infections, HIV I Infection","enrollment":12},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT06158126","phase":"PHASE4","title":"UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-17","conditions":"Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related","enrollment":621},{"nctId":"NCT06646562","phase":"PHASE4","title":"Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.","status":"RECRUITING","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2025-03-03","conditions":"HIV-1 Infected Adults with Controlled Viremia","enrollment":120},{"nctId":"NCT05112939","phase":"PHASE1","title":"A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-16","conditions":"Healthy","enrollment":126},{"nctId":"NCT05549726","phase":"PHASE4","title":"SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-01-02","conditions":"HIV","enrollment":984},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2},{"nctId":"NCT04973254","phase":"NA","title":"Improving Treatment and Retention Adherence in Nontraditional Settings","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2022-02-23","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT05156658","phase":"PHASE4","title":"Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2024-01-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05896748","phase":"PHASE3","title":"Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-11-08","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":94},{"nctId":"NCT06635421","phase":"","title":"The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV","status":"NOT_YET_RECRUITING","sponsor":"MetroHealth Medical Center","startDate":"2024-11-01","conditions":"HIV I Infection","enrollment":164},{"nctId":"NCT05515770","phase":"PHASE3","title":"The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir","status":"RECRUITING","sponsor":"Evandro Chagas National Institute of Infectious Disease","startDate":"2022-09-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06565013","phase":"","title":"Chemsex Health Evaluation With Extended Release System for HIV Treatment","status":"NOT_YET_RECRUITING","sponsor":"Clinique Médicale L'Actuel","startDate":"2024-08","conditions":"HIV","enrollment":50},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT03639311","phase":"PHASE2","title":"Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-09-24","conditions":"HIV Infections","enrollment":97},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT06403865","phase":"","title":"Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine","status":"NOT_YET_RECRUITING","sponsor":"University Paris 7 - Denis Diderot","startDate":"2024-05","conditions":"Quality of Life","enrollment":280},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05949203","phase":"","title":"Oregon PrEP at Home Study","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2023-12-01","conditions":"HIV/AIDS","enrollment":125},{"nctId":"NCT06133686","phase":"PHASE3","title":"Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa","status":"NOT_YET_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2024-04-01","conditions":"HIV","enrollment":400},{"nctId":"NCT05896761","phase":"PHASE3","title":"A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-10-28","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":118},{"nctId":"NCT04001803","phase":"PHASE3","title":"Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-08","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vocabria"],"phase":"phase_3","status":"active","brandName":"Cabotegravir (CAB) LA","genericName":"Cabotegravir (CAB) LA","companyName":"Desmond Tutu HIV Foundation","companyId":"desmond-tutu-hiv-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting intramuscular formulation), HIV-1 prevention in at-risk individuals (PrEP indication under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}